Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
32
COYA Quote, Financials, Valuation and Earnings
Last price:
$5.98
Seasonality move
:
29.02%
Day range:
$5.91 - $6.17
52-week range:
$4.65 - $8.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
25.24x
P/B ratio:
4.62x
Volume:
155.5K
Avg. volume:
214.7K
1-year change:
0.67%
Market cap:
$126M
Revenue:
$3.6M
EPS (TTM):
-$1.10
Analysts' Opinion
-
Consensus RatingCoya Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.07, Coya Therapeutics, Inc. has an estimated upside of 166.97% from its current price of $6.02.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.00 representing 100% downside risk from its current price of $6.02.
Fair Value
-
According to the consensus of 7 analysts, Coya Therapeutics, Inc. has 166.97% upside to fair value with a price target of $16.07 per share.
COYA vs. S&P 500
-
Over the past 5 trading days, Coya Therapeutics, Inc. has underperformed the S&P 500 by -7.81% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Coya Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Coya Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Coya Therapeutics, Inc. reported revenues of $3.6M.
Earnings Growth
-
Coya Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Coya Therapeutics, Inc. reported earnings per share of -$0.13.
Enterprise value:
97.8M
EV / Invested capital:
3.59x
Price / LTM sales:
25.24x
EV / EBIT:
--
EV / Revenue:
24.53x
PEG ratio (5yr expected):
-0.10x
EV / Free cash flow:
-7.73x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$4M
Return On Assets:
-50.15%
Net Income Margin (TTM):
-462.25%
Return On Equity:
-57.41%
Return On Invested Capital:
-57.41%
Operating Margin:
-53.78%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $9.6M | $4M | -- | $3.6M | |
| Gross Profit | -$27.4K | $9.5M | $4M | -$6.8K | $3.6M | |
| Operating Income | -$11M | -$11.1M | -$20.1M | -$4.5M | -$1.9M | |
| EBITDA | -$11M | -$11.1M | -$20.1M | -$4.4M | -$1.9M | |
| Diluted EPS | -$1.24 | -$0.72 | -$1.10 | -$0.26 | -$0.13 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $8.7M | $11.8M | $35.5M | $32M | |
| Total Assets | -- | $9.1M | $11.9M | $35.6M | $32M | |
| Current Liabilities | -- | $2.6M | $1.8M | $2.3M | $3.7M | |
| Total Liabilities | -- | $14.4M | $1.8M | $3.5M | $4.8M | |
| Total Equity | -- | -$5.4M | $10.1M | $32M | $27.3M | |
| Total Debt | -- | $11.8M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$11.2M | -$10.1M | -$12.1M | -$5.5M | -$1.1M | |
| Cash From Investing | -$740K | -$218.2K | -$516K | -- | -$516K | |
| Cash From Financing | $14.1M | $30.5M | $9.7M | -$56.3K | $19.1K | |
| Free Cash Flow | -$11.2M | -$10.1M | -$12.7M | -$5.5M | -$1.6M | |
COYA
Sector
Market Cap
$126M
$28.5M
Price % of 52-Week High
72.62%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-10.18%
-1.33%
1-Year Price Total Return
0.67%
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$6.17
200-day SMA
Sell
Level
$6.09
Bollinger Bands (100)
Sell
Level
5.76 - 6.54
Chaikin Money Flow
Sell
Level
-1.1M
20-day SMA
Sell
Level
$6.04
Relative Strength Index (RSI14)
Sell
Level
48.12
ADX Line
Buy
Level
14.95
Williams %R
Neutral
Level
-63.8298
50-day SMA
Sell
Level
$6.17
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Sell
Level
-1.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (10.65)
Sell
CA Score
(Annual)
Level (-0.5089)
Buy
Beneish M-Score
(Annual)
Level (-4.7452)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (4.8228)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Coya Therapeutics, Inc. is a clinical-stage biotechnology company which engages in developing proprietary medicinal products to modulate the function of regulatory T cells. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.
Stock Forecast FAQ
In the current month, COYA has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The COYA average analyst price target in the past 3 months is $16.07.
-
Where Will Coya Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Coya Therapeutics, Inc. share price will rise to $16.07 per share over the next 12 months.
-
What Do Analysts Say About Coya Therapeutics, Inc.?
Analysts are divided on their view about Coya Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Coya Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is Coya Therapeutics, Inc.'s Price Target?
The price target for Coya Therapeutics, Inc. over the next 1-year time period is forecast to be $16.07 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is COYA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Coya Therapeutics, Inc. is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of COYA?
You can purchase shares of Coya Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Coya Therapeutics, Inc. shares.
-
What Is The Coya Therapeutics, Inc. Share Price Today?
Coya Therapeutics, Inc. was last trading at $5.98 per share. This represents the most recent stock quote for Coya Therapeutics, Inc.. Yesterday, Coya Therapeutics, Inc. closed at $6.02 per share.
-
How To Buy Coya Therapeutics, Inc. Stock Online?
In order to purchase Coya Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get COYA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
COYA
Sector
P/E ratio
--
23.75x
PEG ratio
-0.10x
-0.01x
P/B ratio
4.62x
1.83x
Price / LTM sales
25.24x
1.60x
Growth Metrics
COYA
Sector
Revenue growth
-95.22%
4.85%
Earnings growth
52.16%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.30
-$0.20
Profitability
COYA
Sector
Profitability FY 2024
$3.5M
$3.6M
Return on invested capital
-57.41%
-30.98%
Return on assets
-50.15%
-27.62%
Return on equity
-57.41%
-36.69%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
12
Estimated Next Earnings Date
Feb
11
Balance Sheet
COYA
Sector
Total cash
$28.1M
$27.2M
Short term investments
--
$25.7M
Total assets
$44.3M
$79.7M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
